1. Introduction
===============

The main clinical characteristics in diabetes mellitus as a common health problem in almost all societies in the world is hyperglycemia resulting from disturbances in glucose metabolism processing as well as defects in insulin sensitivity. This phenomenon may lead to long-term damage and also failure in vital organs, such as the eyes, kidneys, cardiovascular system, and cerebrovascular system, and it even can be life-threatening ([@b1-epj-08-2849]). The two types of diabetes, i.e., types 1 and 2, have different pathophysiological fundamentals, i.e., autoimmune destruction of pancreatic islet beta cells leads to absolute insulin deficiency in type 1, whereas the main basis of type 2 is an increase of insulin resistance ([@b2-epj-08-2849]). Iran is one of the main areas where diabetes mellitus is prevalent in the world, and there has been an upward trend in the prevalence of diabetes due to the population's following unhealthy dietary regimens, decreasing their physical activity, and inappropriate lifestyles. The overall prevalence of diabetes is considerably higher in some provinces in Iran, such as Yazd, where the prevalence rate in individuals older than 18 who live in urban areas is estimated to be as high as 14.5% ([@b3-epj-08-2849]). Within the recent decade, it has been suggested that calcium and vitamin D have an essential role related to important metabolic cofactors in glucose metabolism and insulin production and secretion. Recently, it was demonstrated that 25-hydroxy vitamin D is the main element to stimulate insulin secretion through its effect on Vitamin D receptors, which is expressed on insulin secreting cells in the pancreas ([@b4-epj-08-2849]). In this regard, vitamin D deficiency may increase the risk for insulin resistance and thus for developing diabetes mellitus and its related adverse events ([@b5-epj-08-2849]). Adiponectin is a 30 KDa protein synthesized in adipocytes. The central role of adiponectin in regulating glycemic control, improving lipid profile metabolism, and also reducing inflammatory markers, especially in diabetic patients, has been well understood ([@b6-epj-08-2849]). In this regard, some studies have shown that reduced levels of adiponectin may play a role in increasing insulin resistance and developing type 2 diabetes mellitus ([@b7-epj-08-2849], [@b8-epj-08-2849]). Adiponectin deficiency also has been found to be a main precursor for developing diabetes in non-diabetic subjects ([@b9-epj-08-2849]). Soheilykhah et al. indicated that serum concentrations of adiponectin were significantly lower in gestational diabetes compared with patients with normal glucose tolerance ([@b10-epj-08-2849]). Despite the certain roles of both vitamin D and adiponectin in the regulation of insulin sensitivity, the interaction between these two agents has remained uncertain. Because of the importance of these interactions in both diabetic patients and their first-degree relatives, we aimed for the first time to determine whether vitamin D is able to change plasma adiponectin and affect glucose homeostasis and insulin sensitivity in first-degree relatives of subjects with type 2 diabetes.

2. Material and Methods
=======================

2.1. Trial design
-----------------

This study was a randomized, double-blinded clinical trial that was conducted from January 25, 2012 to December 25, 2014.

2.2. Participants
-----------------

This clinical trial was conducted in Clinic of Shahid Sadoughi Hospital (Shahid Sadoughi University of Medical Sciences) and its integrated Internal Medicine Department and Diabetes Research Center. The research population was comprised of first-degree relatives of patients with type 2 diabetes. In this randomized, double-blinded, controlled trial, 64 first-degree relatives of type 2 diabetic patients who were older than 25 and had body mass indices ≥ 25 Kg/m^2^ were included in the study.

2.3. Selection criteria
-----------------------

In this study, patients with FBS less than 126 mg/dl and 2 hour post prandial glucose (2hpp) less than 200 mg/dl were eligible for the study, and they were assigned randomly to receive either vitamin D supplement plus lifestyle change as the intervention group (n = 32) or placebo plus lifestyle change as the control group (n = 32). All of participants were first-degree relatives of people with type 2 diabetes. The exclusion criteria were history of administrating vitamin D or its supplements during the past three months as well as receiving metformin or any other drug that affects insulin resistance. The subjects were invited to come to the Yazd Diabetes Research Center after the study was announced in clinics, offices, and other healthcare centers. After obtaining written informed consent from all of the participants, blood samples were taken in order to measure the baseline serum biomarkers.

2.4. Interventions
------------------

The intervention subjects in the study were told to use one 50,000 IU vitamin D tablet weekly. During the three-month period of study, patients were followed by phone or via Short Message Service (SMS) twice a week to remind them of the instructions. After three months, the patients returned to the Center so that we could reassess their serum biomarkers. Insulin resistance was calculated by the HOMA formula (HOMA= Fasting serum insulin (μU/ml) × Fasting blood sugar (mmol/l)/22.5). Cut-off level for vitamin D was 30 ng/ml. Values greater than 30 ng/ml were considered to be high. The specific kits that were used for detection of vitamin D, adiponectin, and insulin by the Elisa method were 25 Hydroxy Vitamin D EIA kits from Immunodiagnostic System IDS Company, AviBion Human Adiponectin Eli A kit (Acro30) from Ani Biotech Oy Company and Diametra, respectively. A questionnaire was completed by the patients, including demographic data and test results. The rationale for lifestyle modifications was described and applied to both groups. All participants were informed about being at risk for diabetes mellitus, and they were encouraged to have regular exercise (fast walking for 30 minutes daily or swimming), to follow a diet that included the consumption of fresh fruits and vegetables and low-fat dairy products, as well as to avoid the use of excessive carbohydrates and to avoid consuming a high-fat diet.

2.5. Outcomes
-------------

In this study, before beginning the intervention, demographic parameters, age, and gender of the patients were recorded. Before the initiation of the intervention and 12 weeks afterwards, we recorded fasting blood sugar (FBS), 2hpp glucose, triglyceride, cholesterol, 25-hydroxy vitamin D, adiponectin, and fasting insulin level.

2.6. Sample size
----------------

According to relevant studies and by using of the sample size formula, n = σ^2^(Z~α~+Z~β~)^2^/d^2^, and assuming an alpha error of 5% and a study power of 80%, the sample size was determined to be 32 subjects for each group.

2.7. Randomization and blinding
-------------------------------

In this clinical trial, randomization was used with the baseline data of the patients. Randomization was done a staff member who did not have a role in the treatment of the participants. The randomization was done through SPSS 15 software (SPSS, Inc., Chicago, IL, USA). Also, the allocation was done by the researcher who was responsible for the randomization.

2.8. Statistical methods
------------------------

Results were presented as mean ± standard deviation (SD) for quantitative variables, and they were summarized by absolute frequencies and percentages for categorical variables. Categorical variables were compared using the chi-squared test or Fisher's exact test when more than 20% of cells with an expected count of less than 5 were observed. Continuous variables were compared using one-way analysis of the t-test and/or the non-parametric Mann-Whitney test when the data did not appear to have a normal distribution. The change in study biomarkers after treatment protocols compared with baseline values was assessed using the paired t-test. The p-values of 0.05 or less were considered to be statistically significant. All of the statistical analyses were performed using SPSS version 15.0 for Windows (SPSS, Inc., Chicago, IL, USA).

2.9. Research ethics
--------------------

The proposal for this thesis research was presented to the Ethics Committee of Shahid Sadoughi University of Medical Sciences and approved by the Internal Medicine Department. The Ethics Committee approved the study with the number P/17/1/50970 on December 23, 2010. The patients were informed about the objective and nature of the study, and each participant provided written consent prior to the study.

3. Results
==========

Sixty-four patients were recruited for this study that received either vitamin D as the intervention group (n = 32) or placebo as the control group (n = 32). The two groups were similar in average age (38.5 ± 6.8 years versus 41.4 ± 6.9 years, p = 0.12), mean BMI (28.8 ± 2.1 kg/m^2^ versus 28.4 ± 2.8 kg/m^2^, p = 0.16), and male gender (39.0% versus 36.0%, p = 0.80). After three months of study protocols, 53 patients (28 in the intervention group and 25 in the control group) completed the study. [Figure 1](#f1-epj-08-2849){ref-type="fig"} shows the consort flow diagram of the trial. Serum levels of vitamin D increased, while insulin level and, consequently, insulin resistance (calculated by the HOMA formula) significantly decreased in the case group (p-value \<0.001 for all variables) ([Table 1](#t1-epj-08-2849){ref-type="table"}). Although the values of these three biomarkers showed a slight increase in the control group, the changes were not statistically significant. As shown in [Table 1](#t1-epj-08-2849){ref-type="table"}, the levels of the changes in other markers, including adiponectin, FBS, triglycerides, and total cholesterol, were not significant in either of the study groups after completing interventions compared with before interventions.

4. Discussion
=============

Our randomized clinical trial showed significant changes in the serum levels of vitamin D and insulin as well as insulin resistance after three months by using 50,000 IU of vitamin D, however these changes were not statistically significant for the values of other serum biomarkers, including adiponectin, lipid profile, FBS, and BMI. Similar findings were found in some previous studies. In a double-blind study performed by Von Hurst et al. ([@b11-epj-08-2849]), 4000 IU/day of vitamin D given to 42 patients and placebo to 39 patients of non-diabetic Asian women for 6 months led to decrease in insulin resistance in the case group at the end of study, but without significant change in placebo group. Another study by Petchey et al. ([@b12-epj-08-2849]) on 51 patients aged \> 18 with low serum levels of vitamin D showed decrease in insulin resistance in the group who received 2000 IU/day of cholecalcipherol for 6 months. Talaei et al. ([@b13-epj-08-2849]) indicated a decrease in insulin resistance in patients who received 50,000 unit of vitamin D for 8 weeks. Also, another research conducted by Pittaset et al. ([@b14-epj-08-2849]) on 92 patients in which the case group received calcium citrate (500 mg) in addition to vitamin D (700 mg) daily for 3 years showed a significant reduction of insulin resistance in those patients. These results are in agreement with our study despite our shorter duration. In a study done by Nagpal et al. ([@b15-epj-08-2849]) on 100 men aged \> 35, the patients were divided into two groups. The case group received three doses of 120,000 IU vitamin D every two weeks, and the control group received a placebo. Insulin resistance and serum insulin level were unchanged after completion of study, which may have been due to the short duration of the study compared to ours. In research conducted by Gannageet et al. ([@b16-epj-08-2849]) on 381 university students, a direct association was observed between serum levels of vitamin D and adiponectin. Similar results were found in Liu et al.'s ([@b17-epj-08-2849]) study, which was performed on 808 non-diabetic patients. The results of these studies are in disagreement with our study, probably due to different study design and smaller sample sizes. In Von Hurst's ([@b10-epj-08-2849]) and Pittas' ([@b12-epj-08-2849]) studies, there were no significant changes in mean serum lipids. These findings resembled those of our study. In addition, Pittas' ([@b12-epj-08-2849]) research showed significant changes in FBS level, which may be described by the long duration of the trial (3 years). In other study performed by Afkhami-Ardekani et al. ([@b18-epj-08-2849]) on 84 patients with type 2 diabetes, it was indicated that receiving 1000 mg of vitamin C daily for six weeks may reduce blood glucose and lipids.

5. Conclusions
==============

Based on our results, we can conclude that vitamin D may decrease serum insulin and insulin resistance in patients at risk for diabetes. But to evaluate the effects of vitamin D on serum adiponectin, more clinical trials are needed. In our study, we observed significant changes in serum levels of vitamin D and insulin as well as insulin resistance after three months use of 50,000 IU of vitamin D, but these changes were not statistically significant for serum adiponectin, lipids, FBS, and BMI. More study is required before we could recommend the consumption of vitamin D to these subjects for prevention of diabetes in persons at risk for type 2 diabetes.
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Comparison of test results between the two groups before and after intervention

  Variables              Before Intervention   After Intervention   p-value[1](#tfn1-epj-08-2849){ref-type="table-fn"}   p-value[2](#tfn2-epj-08-2849){ref-type="table-fn"}   
  ---------------------- --------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------- ---------
  Vitamin D (ng/ml)      Study group           19.0 ± 2.2           69.0 ± 7.5                                           \<0.001                                              \<0.001
  Control                23.0 ± 1.8            25.0 ± 2.2           0.28                                                                                                      
  Insulin (μU/ml)        Study group           10.6 ± 3.0           7.1 ± 2.9                                            \<0.001                                              \<0.001
  Control                6.77 ± 2.1            7.0 ± 1.8            0.11                                                                                                      
  Insulin Resistance     Study group           2.3 ± 0.7            1.5 ± 0.5                                            \<0.001                                              \<0.001
  Control                1.6 ± 0.2             1.9 ± 0.3            0.24                                                                                                      
  Adiponectin (ng/ml)    Study group           4.6 ± 4.2            4.2 ± 3.7                                            0.86                                                 0.36
  Control                5.1 ± 4.3             3.2 ± 2.8            0.12                                                                                                      
  Cholesterol (mg/dl)    Study group           192 ± 28             192 ± 39                                             0.97                                                 0.86
  Control                196 ± 32              199 ± 30             0.66                                                                                                      
  Triglyceride (mg/dl)   Study group           177 ± 137            186 ± 128                                            0.72                                                 0.56
  Control                163 ± 54              154 ± 38             0.49                                                                                                      
  FBS (mg/dl)            Study group           94.2 ± 9.4           90.0 ± 18.6                                          0.92                                                 0.29
  Control                97.2 ± 11.2           94.6 ± 12.5          0.17                                                                                                      

p-value within groups,

p-value between groups
